News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Holding AG (JOBS), Genentech, Inc. (JOBS) Said Two Drugs Don’t Boost Lung Cancer Survival
October 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH/LONDON, Oct 6 (Reuters) - Roche Holding AG and Genentech Inc said on Monday a study into the benefits of combining their Tarceva and Avastin drugs for lung cancer patients did not show an increase in overall survival.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Genentech, Inc.
MORE ON THIS TOPIC
Rare diseases
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
March 12, 2026
·
2 min read
·
Tristan Manalac
Clinical research
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders
March 12, 2026
·
3 min read
·
Tristan Manalac
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
March 10, 2026
·
3 min read
·
Tristan Manalac
